Publication: Towards the elimination of viral hepatitis in Thailand by the year 2030
2
Issued Date
2020-09-01
Resource Type
ISSN
20556659
20556640
20556640
Other identifier(s)
2-s2.0-85090895346
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Virus Eradication. Vol.6, No.3 (2020)
Suggested Citation
Nawarat Posuwan, Nasamon Wanlapakorn, Palittiya Sintusek, Rujipat Wasitthankasem, Kittiyod Poovorawan, Sompong Vongpunsawad, Yong Poovorawan Towards the elimination of viral hepatitis in Thailand by the year 2030. Journal of Virus Eradication. Vol.6, No.3 (2020). doi:10.1016/j.jve.2020.100003 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/59118
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Towards the elimination of viral hepatitis in Thailand by the year 2030
Abstract
© 2020 The Author(s) Viral hepatitis is a global problem with mortality comparable to HIV, tuberculosis and malaria. The WHO aims to eliminate hepatitis B (HBV) and hepatitis C (HCV) by 2030. Improved socioeconomic status of developing countries such as Thailand has reduced the incidence and morbidity associated with hepatitis A. Since the beginning of hepatitis B vaccination in all Thai newborns in 1992, at least 95% of one-year-old are currently receiving 3–4 hepatitis B doses. The second vaccination of newborns of carrier mothers at 1 month of age has contributed to an effective reduction in mother-to-child transmission. Universal vaccination, blood donation screening, and decreasing needle sharing have reduced hepatitis B infection. Under the test-to-treat model, cost-effective screening at the point-of-care (health center or village hospital) is recommended for adults >30 years-old. Following referral to a tertiary healthcare center for a treatment plan in developing disease management plan, its implementation treatment to a by trained healthcare professionals is preferably administered at the point-of-care. Hepatitis C prevalence is also decreasing as a result of blood-borne pathogen awareness. Current hepatitis C infection is highest for adults >35 years who were born prior to 1983, with screening is recommend once in their lifetime. Treatment strategy recommendation follows that of hepatitis B. The availability of direct antiviral agent with high cure rate is expected to contribute to the reduction in hepatitis C transmission and mortality set forth by the WHO policy. Thus, ensuring the successful planning of hepatitis elimination in Thailand requires pilot regional assessment prior to national implementation.